HighGravityDataBioMarin Pharmaceutical — Feb 19, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-25-000004
Showing in the filing
Operating cash flows
“more than $1.25 billion”
Period
FY2027
Measure
GAAP-tied
Source
Prose
All guidance in this release · 14
Revenue and profitability growth for FY2025
“Double-Digit”
VOXZOGO country availability for FY2027
“more than 60 countries”
VOXZOGO Revenue CAGR for FY2023
“exceeding 25%”
Enzyme Therapies long-term growth outlook (C… for the long term
“high single-digit CAGR”
Cost transformation program size for FY2024
“$500 million”
Non-GAAP Operating Margin for FY2026
“40%”
Total Revenues for FY2027
“approximately $4 billion”
Non-GAAP Operating Margin growth for FY2025
“14% (3.9 percentage points) Y/Y at the mid-point of guidance”
Operating cash flows for FY2027
“more than $1.25 billion”
Total Revenues for FY2025
“$3,100 to $3,200”
Non-GAAP Operating Margin % for FY2025
“32% to 33%”
Non-GAAP Diluted EPS for FY2025
“$4.20 to $4.40”
VOXZOGO contribution to full-year 2025 Total… for FY2025
“$900 million to $950 million”
Weighted-Average Diluted Shares Outstanding … for FY2025
“approximately 200 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
Total cash and investments at the end of the fourth quarter were approximately $1.7 billion, and with anticipated increasing profitability, BioMarin is positioned to generate increasing operating cash flow into the future, targeting more than $1.25 billion operating cash flows per year starting in 2027. 3 Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 % Change 2024 2023 % Change Total Revenues $747 $646 16% $2,854 $2,419 18% Net Product Revenues by Product: VOXZOGO $208 $146 42% $735 $470 56% Enzyme Therapies: VIMIZIM $191 $176 9% $740 $701 6% NAGLAZYME 110 98 12% 480 420 14% PALYNZIQ 100 88 14% 355 304 17% BRINEURA 48 44 9% 169 162 4% ALDURAZYME 39 43 (9)% 184 131 40% Total Enzyme Therapies Revenue $488 $449 9% $1,928 $1,718 12% KUVAN $28 $37 (24)% $121 $181 (33)% ROCTAVIAN ® $11 $3 267% $26 $3 767% GAAP Net Income $125 $20 525% $427 $168 154% Non-GAAP Income (1) $180 $95 89% $686 $405 69% GAAP Operating Margin % (2) 21.6% 4.2% 17.0% 7.7% Non-GAAP Operating Margin % (1) 31.1% 17.2% 28.6% 19.4% GAAP Diluted Earnings per Share (EPS) $0.64 $0.11 482% $2.21 $0.87 154% Non-GAAP Diluted EPS (1) $0.92 $0.49 88% $3.52 $2.08 69% December 31, 2024 December 31, 2023 Total cash, cash equivalents & investments $ 1,659 $ 1,685 (1) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.